SLU-PP-332

Preclinical only Weight Loss & Metabolism 2 sources

SLU-PP-332 is a novel investigational compound known as an 'exercise mimetic' that activates estrogen-related receptors (ERRs). Preclinical research indicates it can enhance endurance, increase fat oxidation, and promote weight loss without altering food intake or requiring physical exercise. It is currently being studied for its potential to treat metabolic disorders and muscle wasting conditions.

01Dosing reference

Amount

Not established for humans (Preclinical: 25 mg/kg in mice)

Frequency

Unknown for humans

Cycle

Unknown for humans

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Pan-ERR Activation

SLU-PP-332 binds to and activates all three estrogen-related receptor isoforms (ERRα, ERRβ, and ERRγ).

Metabolic Gene Transcription

This activation upregulates the expression of genes responsible for mitochondrial biogenesis, fatty acid oxidation, and oxidative metabolism in skeletal muscle.

Exercise-Like Adaptation

The body responds by shifting energy preference to fat burning and increasing endurance capacity, mimicking the physiological effects of aerobic exercise.

03Human evidence

No human clinical trials have been published to date.

Current research is strictly limited to animal models and in vitro studies.

04Preclinical evidence

Increased running endurance and muscle fiber type shifting.

In mouse models, administration of SLU-PP-332 increased the proportion of oxidative type IIa muscle fibers and significantly improved treadmill running distance.

Weight loss and reduced fat mass in diet-induced obesity.

Obese mice treated with the compound lost weight and fat mass while maintaining lean muscle, without any reduction in food intake.

05What is known vs. unknown

Reasonably established

Acts as a pan-ERR (estrogen-related receptor) agonist.
Functions as an 'exercise mimetic' by activating metabolic pathways typically stimulated by physical activity.
Increases skeletal muscle fat oxidation and energy expenditure.
Demonstrates potential in preclinical models for treating obesity and metabolic syndrome.

Unknowns & limits

Lack of human safety and efficacy data.
Long-term effects of chronic ERR activation on cardiovascular and endocrine systems are unknown.
Optimal dosing and administration routes for humans have not been established.

06Safety & regulatory context

Regulatory statusSLU-PP-332 is strictly an experimental research chemical and is not approved by the FDA or any regulatory body for human consumption. Its safety profile in humans is entirely unknown. Potential risks could include unforeseen endocrine disruption or cardiovascular strain due to its profound metabolic effects. It should only be used in controlled laboratory settings for in vitro or animal research.

07Compared with GW501516 (Cardarine)

SLU-PP-332 vs. GW501516 (Cardarine)

Key difference

While both are considered exercise mimetics, SLU-PP-332 targets estrogen-related receptors (ERRs), whereas GW501516 targets the peroxisome proliferator-activated receptor delta (PPARδ).

When researchers discuss each

Researchers discuss GW501516 when studying PPARδ-mediated endurance and lipid metabolism, while SLU-PP-332 is discussed in the context of ERR-driven mitochondrial biogenesis and metabolic syndrome treatments.

08Glossary

Exercise Mimetic

A compound that replicates the physiological benefits of physical exercise, such as increased endurance and fat burning, without actual physical activity.

Estrogen-Related Receptors (ERRs)

A group of nuclear receptors that regulate cellular energy metabolism and mitochondrial function, despite not binding to estrogen.

Mitochondrial Biogenesis

The process by which cells increase their number of mitochondria, enhancing their ability to produce energy.

09Knowledge check

Q1Which specific receptors does SLU-PP-332 target to exert its metabolic effects?

Q2What is the primary physiological outcome observed in preclinical studies of SLU-PP-332?

Q3Which interpretation about SLU-PP-332’s readiness for human research is best supported by the dossier?

Q4When researchers compare SLU-PP-332 with GW501516 (Cardarine), what is the key mechanistic distinction noted in the dossier?

Q5Which statement best reflects the dossier’s safety and regulatory context for SLU-PP-332?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.